NCT03077607View on ClinicalTrials.gov

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

December 19, 2017

Study Completion Date

January 20, 2018

Conditions
Advanced Solid Tumors
Interventions
DRUG

Talazoparib

Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose

DRUG

Itraconazole

100 mg oral dose

DRUG

Rifampin

600 mg oral dose

Trial Locations (7)

1077

PRA Magyarorszag Kft, Fazis I-es Klinikai Farmakologiai Vizsgalohely, Budapest

119435

I.M. Sechenov First Moscow State Medical University, Moscow

119991

I.M. Sechenov First Moscow State Medical University, Moscow

150054

"State budget healthcare institution of Yaroslavl region Regional clinical oncology hospital", Yaroslavl

197342

"BioEq LLC", Saint Petersburg

MD2025

ARENSIA Exploratory Medicine Phase I Unit, PMSI Institute of Oncology, Chisinau

02-801

Szpital LUX MED, Warsaw

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT03077607 - A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter